Ciric To

发表

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

Henry W. Long, R. Beroukhim, C. Paweletz, 2020, Cancer cell.

Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.

P. Jänne, N. Gray, M. Eck, 2020, Angewandte Chemie.

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

David A. Scott, Anna M. Schmoker, P. Jänne, 2022, Nature Communications.

Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations

P. Jänne, N. Gray, M. Eck, 2020, Angewandte Chemie.

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.

David A. Scott, P. Jänne, N. Gray, 2022, Bioorganic & medicinal chemistry letters.

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor

Anna M. Schmoker, P. Jänne, M. Eck, 2020 .

Synthetic triterpenoids inhibit GSK3β activity and localization and affect focal adhesions and cell migration.

G. M. Di Guglielmo, M. Prado, Ciric To, 2017, Biochimica et biophysica acta. Molecular cell research.

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer

G. Daley, C. Paweletz, P. Jänne, 2021, Science Translational Medicine.

The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice

M. Sporn, Eun-Hee Kim, K. Liby, 2014, Cancer Prevention Research.

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.

P. Jänne, Kwok-Kin Wong, N. Gray, 2019, Cancer discovery.

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

David A. Scott, P. Jänne, N. Gray, 2022, Nature Cancer.

Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.

Anna M. Schmoker, S. Knapp, P. Jänne, 2021, Journal of medicinal chemistry.

Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

M. Sporn, C. Ringelberg, K. Liby, 2015, Carcinogenesis.

The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid-Imidazolide Alters Transforming Growth Factor β-dependent Signaling and Cell Migration by Affecting the Cytoskeleton and the Polarity Complex*

M. Sporn, T. Pawson, J. Wrana, 2008, Journal of Biological Chemistry.

Brief Report: EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1st generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples.

C. Paweletz, P. Jänne, S. Kobayashi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PARP Inhibitors for Chemoprevention—Reply

M. Sporn, K. Liby, Ciric To, 2014, Cancer Prevention Research.

Synthetic Triterpenoids Target the Arp2/3 Complex and Inhibit Branched Actin Polymerization*

G. M. Di Guglielmo, B. Shilton, Ciric To, 2010, The Journal of Biological Chemistry.

Discovery of a potent dual ALK and EGFR T790M inhibitor.

P. Jänne, N. Gray, H. Choi, 2017, European journal of medicinal chemistry.

Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.

David A. Scott, P. Jänne, N. Gray, 2019, ACS medicinal chemistry letters.

EGFR -mutated lung cancers resistant to osimertinib through EGFR -C797S respond to 1 st generation reversible EGFR inhibitors but eventually acquire EGFR -T790M/C797S in preclinical models and clinical samples

C. Paweletz, P. Jänne, S. Kobayashi, 2019 .

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology

P. Jänne, M. Eck, D. Heppner, 2023, Molecular Pharmacology.